Eli Lilly and Company (LLY · NYSE)

Eli Lilly delivered 47.7% year-over-year revenue growth with TTM revenue of $79.67B, and beat analyst estimates in all of its last four quarters, most recently reporting $8.38 EPS versus $6.01 expected. Margins are exceptional — 83.4% gross, 54.2% operating, and 33.5% profit — driving a 102.3% ROE, while leverage remains modest at 1.3x debt/EBITDA with $8.89B in cash and $7.76B in quarterly free cash flow. The market is paying up for that performance: a $1.05T market cap, 39.69 P/E, and 13.25 price-to-sales, with the stock at $1,183.46 sitting 7.6% below its 52-week high and 10.9% above its 200-day moving average. A notable competitive overhang emerged as Novo Nordisk's CagriSema outperformed Lilly's Zepbound on weight loss in a late-stage trial.